Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients with Chronic Kidney Disease

18-Apr-2007

Genzyme Corp. announced that a recently completed study of Renvela(TM) (sevelamer carbonate) achieved its primary endpoint, demonstrating a statistically significant reduction in serum phosphorus for hyperphosphatemic patients with chronic kidney disease who are not on dialysis.

Patients treated with Renvela also achieved a significant reduction in calcium-phosphorus product and in LDL cholesterol. The drug was well tolerated with a safety profile consistent with the clinical experience of patients on dialysis using Renagel® (sevelamer hydrochloride). The multi-center, single arm, open-label trial involved 49 patients at multiple study sites throughout Europe and Australia.

Renvela is a buffered form of Renagel. Like Renagel, Renvela is a calcium-free, metal-free, non-absorbed phosphate binder. A New Drug Application for Renvela is currently under review by the US Food and Drug Administration for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance